Menu
Search
|

Menu

Close
X

Spectrum Pharmaceuticals Inc SPPI.OQ (NASDAQ Stock Exchange Global Select Market)

23.83 USD
+0.13 (+0.55%)
As of 3:48 PM BST
chart
Previous Close 23.70
Open 23.70
Volume 95,910
3m Avg Volume 557,393
Today’s High 23.93
Today’s Low 23.35
52 Week High 23.93
52 Week Low 7.22
Shares Outstanding (mil) 93.94
Market Capitalization (mil) 1,341.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
30
FY17
128
FY16
146
FY15
163
EPS (USD)
FY18
-0.157
FY17
-0.686
FY16
-0.950
FY15
-0.780
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
10.16
5.73
Price to Book (MRQ)
vs sector
5.84
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
50.39
16.84
LT Debt to Equity (MRQ)
vs sector
50.39
12.51
Return on Investment (TTM)
vs sector
-22.34
14.61
Return on Equity (TTM)
vs sector
-36.04
16.34

EXECUTIVE LEADERSHIP

Stuart Krassner
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Joseph Turgeon
President, Chief Executive Officer, Director, Since 2017
Salary: $600,000.00
Bonus: $342,000.00
Kurt Gustafson
Chief Financial Officer, Executive Vice President, Since 2013
Salary: $500,000.00
Bonus: $237,500.00
Thomas Riga
Chief Operating Officer, Chief Commercial Officer, Executive Vice President, Since 2017
Salary: $420,000.00
Bonus: $275,000.00
Keith McGahan
Senior Vice President, Chief Legal Officer and Corporate Secretary, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11500 S Eastern Ave Ste 240
HENDERSON   NV   89052-5576

Phone: +1702.8356300

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

SPONSORED STORIES